NCT05967884 - PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions

Breast Cancer

Interventions

DRUG

Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab

Arm A: Cemiplimab: 350mg IV x 1 dose administered prior to surgery Arm B: Cemiplimab + Dupilumab: Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery

Trial Locations (2)

K1Y 4E9

The Ottawa Hospital Research Institute and Cancer Center, Ottawa

M5G 0A3

Ontario Institute for Cancer Research, Toronto